MCID: NRD001
MIFTS: 39

Neurodermatitis

Categories: Neuronal diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Neurodermatitis

MalaCards integrated aliases for Neurodermatitis:

Name: Neurodermatitis 11 43 14 16 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:3309
MeSH 43 D009450
NCIt 49 C111963
SNOMED-CT 68 156383005
UMLS 71 C0027822

Summaries for Neurodermatitis

Disease Ontology: 11 A dermatitis that is characterized by chronic itching or scaling.

MalaCards based summary: Neurodermatitis is related to occupational dermatitis and alopecia areata. An important gene associated with Neurodermatitis is FLG (Filaggrin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Interleukin-4 and Interleukin-13 signaling. The drugs Lidocaine and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, adrenal cortex and cortex, and related phenotypes are growth/size/body region and integument

Related Diseases for Neurodermatitis

Diseases related to Neurodermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 occupational dermatitis 30.3 IL31 FLG
2 alopecia areata 30.2 IL4 IL13 FLG
3 chronic rhinitis 30.2 TAC1 IL4 IL13
4 dermatitis, atopic 30.2 TSLP TAC1 IL4 IL31RA IL31 IL13
5 psoriasis 30.1 IL4 IL31 IL13 FLG CCL17
6 ige responsiveness, atopic 30.1 IL4 IL13
7 dermatitis 30.0 TSLP IL4 IL31RA IL31 IL13 FLG
8 blepharoconjunctivitis 30.0 IL4 IL13
9 urticaria 29.8 TSLP TAC1 IL4 IL31 IL13
10 scabies 29.8 IL4 IL31 IL13 FLG
11 food allergy 29.8 TSLP IL4 IL13 FLG
12 chronic conjunctivitis 29.7 TSLP IL4 IL13
13 milk allergy 29.7 TSLP IL4 IL13
14 common cold 29.7 TSLP IL4 IL13
15 allergic rhinitis 29.5 TAC1 IL4 IL13 CCL17
16 rhinitis 29.5 TSLP POMC IL4 IL13 FLG
17 erythema multiforme 29.4 IL4 IL13 CCL17
18 respiratory allergy 28.9 TSLP IL4 IL13 FLG CCL17
19 skin disease 28.9 TSLP TAC1 POMC IL4 IL31 IL13
20 allergic disease 28.6 TSLP TAC1 IL4 IL13 FLG CCL17
21 asthma 28.5 TSLP TAC1 POMC IL4 IL31 IL13
22 allergic contact dermatitis 28.4 TSLP IL4 IL31RA IL31 IL13 FLG
23 contact dermatitis 28.1 TSLP TAC1 IL4 IL31RA IL31 IL13
24 prurigo nodularis 11.0
25 psoriasis 1 10.6
26 psoriasis 2 10.6
27 psoriasis 7 10.6
28 psoriasis 11 10.6
29 psoriasis 13 10.6
30 cataract 10.3
31 dermatitis, atopic, 2 10.2
32 chromium allergic contact dermatitis 10.2 IL4 IL13
33 thunderstorm triggered asthma 10.2 IL4 IL13
34 vernal keratoconjunctivitis 10.2 IL4 IL13
35 papillary conjunctivitis 10.2 IL4 IL13
36 cow milk allergy 10.2 IL4 IL13
37 loiasis 10.2 IL4 IL13
38 eosinophilic meningitis 10.2 IL4 IL13
39 mikulicz disease 10.2 IL4 IL13
40 ascaris lumbricoides infection 10.2 IL4 IL13
41 elephantiasis 10.2 IL4 IL13
42 giant papillary conjunctivitis 10.2 IL4 IL13
43 toxocariasis 10.2 IL4 IL13
44 dacryoadenitis 10.2 IL4 IL13
45 eosinophilic gastritis 10.1 TSLP IL13
46 mucocutaneous leishmaniasis 10.1 IL4 IL13
47 urinary schistosomiasis 10.1 IL4 IL13
48 penicillin allergy 10.1 IL4 IL13
49 pollen allergy 10.1 IL4 IL13
50 alopecia 10.1

Graphical network of the top 20 diseases related to Neurodermatitis:



Diseases related to Neurodermatitis

Symptoms & Phenotypes for Neurodermatitis

MGI Mouse Phenotypes related to Neurodermatitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.61 CCL17 CIR1 IL13 IL31RA IL4 MRGPRX1
2 integument MP:0010771 9.23 CIR1 IL13 IL4 MRGPRX1 POMC TAC1

Drugs & Therapeutics for Neurodermatitis

Drugs for Neurodermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2 Antirheumatic Agents Phase 4
3 Evening Primrose Phase 4
4 Antimetabolites Phase 4
5 Hypolipidemic Agents Phase 4
6 Anti-Inflammatory Agents, Non-Steroidal Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Analgesics, Non-Narcotic Phase 4
9 Analgesics Phase 4
10 Lipid Regulating Agents Phase 4
11 Olive Phase 4
12 Linoleate Phase 4
13 Dermatologic Agents Phase 4
14 Anti-Arrhythmia Agents Phase 4
15 Sodium Channel Blockers Phase 4
16 Anesthetics, Local Phase 4
17 Anesthetics Phase 4
18 Diuretics, Potassium Sparing Phase 4
19
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
20
Crofelemer Approved Phase 3 33507-63-0, 148465-45-6 36511 44359816
21
Nalbuphine Approved Phase 2, Phase 3 20594-83-6 5311304
22
Serlopitant Investigational Phase 3 860642-69-9 23653789
23 Calcineurin Inhibitors Phase 3
24 Neurotransmitter Agents Phase 3
25 Neurokinin-1 Receptor Antagonists Phase 3
26
Neurokinin A Phase 3 86933-74-6 55582
27 Analgesics, Opioid Phase 2, Phase 3
28 Narcotics Phase 2, Phase 3
29
Apremilast Approved, Investigational Phase 2 608141-41-9 10151715 11561674
30
Abrocitinib Approved, Investigational Phase 2 1622902-68-4 78323835
31 Immunologic Factors Phase 2
32 Immunoglobulins Phase 2
33 Antibodies, Monoclonal Phase 2
34 Antibodies Phase 2
35 Phosphodiesterase Inhibitors Phase 2
36 Phosphodiesterase 4 Inhibitors Phase 2
37 Histamine H1 Antagonists Phase 2
38 Histamine Antagonists Phase 2
39 Immunosuppressive Agents Phase 2
40 Protein Kinase Inhibitors Phase 2
41 Pharmaceutical Solutions Phase 2
42
Citalopram Approved 59729-32-7, 59729-33-8 2771
43
Dexetimide Withdrawn 21888-98-2 30843
44 Psychotropic Drugs
45 Antidepressive Agents
46 Serotonin Uptake Inhibitors
47
Serotonin Investigational, Nutraceutical 50-67-9 5202

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study) Completed NCT00878670 Phase 4 EPOGAM 1000
2 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
3 Prospective, Controlled Three-Armed Study About Effectiveness and Compatibility of Silver-Containing Textiles for Treatment of Acute Neurodermatitis Completed NCT00196430 Phase 3 corticosteroid
4 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Completed NCT04183335 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
5 A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable Completed NCT04202679 Phase 3 Dupilumab SAR231893;Placebo;Moisturizers;Low to medium potent topical corticosteroids;Topical calcineurin inhibitors
6 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Completed NCT03677401 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
7 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis Completed NCT03546816 Phase 3 5mg Serlopitant Tablets;Placebo Tablets
8 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Completed NCT04501679 Phase 3 Nemolizumab;Placebo
9 An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174432 Phase 2, Phase 3 nalbuphine HCl ER
10 A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients Completed NCT02174419 Phase 2, Phase 3 nalbuphine HCl ER tablets 90 mg BID;nalbuphine HCl ER tablets 180 mg BID;Placebo tablets BID
11 A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects With Prurigo Nodularis Recruiting NCT05052983 Phase 3 Nemolizumab;Placebo
12 A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Active, not recruiting NCT04501666 Phase 3 Nemolizumab 30 mg;Placebo
13 A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis Enrolling by invitation NCT04204616 Phase 3 Nemolizumab
14 Apremilast as Anti-pruritic Treatment in Patients With Prurigo Nodularis Unknown status NCT03576287 Phase 1, Phase 2 Apremilast Oral Product
15 A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis Completed NCT03568136 Phase 2 Secukinumab 300 mg;Placebo
16 KPL-716-C202: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Pilot Study to Investigate the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Diseases Characterized by Chronic Pruritus Completed NCT03858634 Phase 2 KPL-716;Placebo
17 An Open Label, Single Center Study to Assess the Safety and Efficacy of a 24 Week Treatment Course of CC-10004 in Adults With Recalcitrant Nodularis Completed NCT00869089 Phase 2 CC-10004
18 Efficacy, Safety, and Tolerability of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Completed NCT05038982 Phase 2 Abrocitinib
19 A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis Completed NCT02196324 Phase 2 serlopitant;Placebo
20 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis Recruiting NCT05061693 Phase 2 INCB054707;Placebo
21 A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis Active, not recruiting NCT03816891 Phase 2 vixarelimab;Placebo
22 A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis Recruiting NCT04944862 Phase 1 Normal saline
23 Double-blind, Vehicle-controlled, Phase I Study to Evaluate Safety and Efficacy of a 0.3% and 1% Topical Formulation of KM-001 for Management of Moderate to Severe Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC) Recruiting NCT05454462 Phase 1 IMP Application KM-001
24 Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing Unknown status NCT04681300
25 Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis Unknown status NCT00532519 citalopram (cipralex)
26 Diagnostic Accuracy of "Three Rings Vulvoscopy" for Detection of Vulvar Dermatosis Completed NCT02732145

Search NIH Clinical Center for Neurodermatitis

Cochrane evidence based reviews: neurodermatitis

Genetic Tests for Neurodermatitis

Anatomical Context for Neurodermatitis

Organs/tissues related to Neurodermatitis:

MalaCards : Skin, Adrenal Cortex, Cortex, Spinal Cord, Thymus, Eye, Pituitary

Publications for Neurodermatitis

Articles related to Neurodermatitis:

(show top 50) (show all 833)
# Title Authors PMID Year
1
A Case of Chromoblastomycosis Caused by Fonsecaea monophora Misdiagnosed as Neurodermatitis. 62
35881262 2022
2
Diffuse Pulmonary Meningotheliomatosis in a Patient With Neurodermatitis With Prurigo Nodularis. 62
36135781 2022
3
Vulvar Neurodermatitis in a Postmenopausal African-American Patient: A Case Report. 62
35534430 2022
4
The pediatric dermatology psychosocial screen: Promoting psychosocial coping and early identification of mental illness in pediatric dermatology patients. 62
35178722 2022
5
Prominent Role of Type 2 Immunity in Skin Diseases: Beyond Atopic Dermatitis. 62
34261335 2022
6
Sexual Self-Esteem and Psychological Burden of Adults With Neurofibromatosis Type 1. 62
35756263 2022
7
Linking Dentistry and Chronic Inflammatory Autoimmune Diseases - Can Oral and Jawbone Stressors Affect Systemic Symptoms of Atopic Dermatitis? A Case Report. 62
35782227 2022
8
Diagnosis of Primary Cutaneous Amyloidosis by Rapid 4,6-Diamidino-2-Phenylindole Staining. 62
34515096 2022
9
The Efficacy and Safety of Acupuncture in the Treatment of Neurodermatitis: A Systematic Review and Meta-Analysis. 62
36091587 2022
10
Risk Factors for Progression of Keratoconus and Failure Rate After Corneal Cross-linking. 62
34914558 2021
11
Change in exposure of children to second-hand smoke with impact on children's health and change in parental smoking habits after smoking ban in Bavaria - a multiple cross-sectional study. 62
34801027 2021
12
What are the highest yielding search strategy terms for systematic reviews in atopic dermatitis? A systematic review. 62
33221950 2021
13
Mouse models of atopic dermatitis: a critical reappraisal. 62
33368555 2021
14
Prurigo nodularis comparative treatment outcome in patients attending a tertiary hospital in northern Tanzania. 62
33559259 2021
15
Scabies-induced lichen simplex chronicus misdiagnosed as psychogenic pruritus: a case report. 62
33593424 2021
16
Biologics for atopic diseases: Indication, side effect management, and new developments. 62
33426426 2021
17
Awareness of psychodermatology in Indian dermatologists: A South Indian perspective. 62
32677246 2020
18
Cupping for neurodermatitis: A protocol of systematic review and meta-analysis. 62
33019475 2020
19
A systematic Analysis of Evaluation Methods for Inpatient Children and Adolescents Rehabilitation Programs. 62
32588415 2020
20
Impact of COVID-19 Pandemic on Dermatologists and Dermatology Practice. 62
32695687 2020
21
[The health status of children and adolescents with migration background in Germany : Results from KiGGS Wave 2]. 62
31529190 2019
22
Derailed Ceramide Metabolism in Atopic Dermatitis (AD): A Causal Starting Point for a Personalized (Basic) Therapy. 62
31443157 2019
23
Mindfulness-Based Cognitive Hypnotherapy and Skin Disorders. 62
29771216 2018
24
Perianal Dermatitis. 62
28338543 2017
25
[Neurodermatitis : Atopy of the skin]. 62
28447153 2017
26
Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta-analysis, and recommendation for uniform use of 'atopic dermatitis'. 62
27392131 2016
27
[Risk hidden in the small print? : Some food additives may trigger pseudoallergic reactions]. 62
27173908 2016
28
Hypertrophic lichen planus versus prurigo nodularis: a dermoscopic perspective. 62
27222766 2016
29
[Definition and clinic of the allergic rhinitis]. 62
27120868 2016
30
["Neurodermatitis is often considered a childhood illness"]. 62
27084140 2016
31
Rasch analysis holds no brief for the use of the Dermatology Life Quality Index (DLQI) in Chinese neurodermatitis patients. 62
26841932 2016
32
Inhibition of IKK-β by epidioxysterols from the flowers of Calotropis gigantea (Niu jiao gua). 62
26937251 2016
33
Recent Advances in Pharmacotherapeutic Paradigm of Mild to Recalcitrant Atopic Dermatitis. 62
27910751 2016
34
Leprosy in the Bible. 62
26773616 2016
35
[Multiple dredging method combined with regulating internal organs and spinal cord for 18 cases of neurodermatitis]. 62
26964167 2015
36
Acupuncture as a Treatment Modality in Dermatology: A Systematic Review. 62
26115180 2015
37
PSYCHOSOMATIC ASPECTS IN PATIENTS WITH DERMATOLOGIC DISEASES. 62
26087735 2015
38
[No scratching, please: 6 strategies to control neurodermatitis itch]. 62
26314172 2015
39
Dermatological Complaints of the Elderly Attending a Dermatology Outpatient Clinic in Turkey: A Prospective Study over a One-year Period. 62
26724880 2015
40
Dermatologic manifestations of fibromyalgia. 62
24420725 2014
41
[Bibliometrics analysis on researches of illness spectrum for acu-moxibustion therapy and prospect]. 62
25069204 2014
42
[Pseudo-condylomatous neurodermatitis of the anal margin]. 62
25317228 2014
43
Autoerythrocyte sensitization syndrome presenting with general neurodermatitis. 62
23956968 2013
44
A case of neurodermatitis circumscipta of scalp presenting as patchy alopecia. 62
24403775 2013
45
Use of lenalidomide in treating refractory prurigo nodularis. 62
23545923 2013
46
Propolis: a wonder bees product and its pharmacological potentials. 62
24382957 2013
47
Quality of life of patients with neurodermatitis. 62
23533146 2013
48
Autoerythrocyte sensitization syndrome presenting with general neurodermatitis: factitious purpura or psychophysiological entity? 62
23205328 2012
49
Real-life effect of classical homeopathy in the treatment of allergies: A multicenter prospective observational study. 62
22138796 2012
50
Sexual dysfunction in female patients with neurodermatitis. 62
20864649 2011

Variations for Neurodermatitis

Expression for Neurodermatitis

Search GEO for disease gene expression data for Neurodermatitis.

Pathways for Neurodermatitis

GO Terms for Neurodermatitis

Biological processes related to Neurodermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 macrophage activation GO:0042116 9.73 IL4 IL13
2 response to pain GO:0048265 9.71 TRPA1 TAC1
3 positive regulation of interleukin-13 production GO:0032736 9.67 TSLP IL4
4 positive regulation of interleukin-10 production GO:0032733 9.63 TSLP IL4 IL13
5 positive regulation of mast cell degranulation GO:0043306 9.62 IL4 IL13
6 negative regulation of macrophage activation GO:0043031 9.56 IL4 IL31RA
7 negative regulation of complement-dependent cytotoxicity GO:1903660 9.26 IL4 IL13
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.23 TSLP IL4 IL31RA IL13

Molecular functions related to Neurodermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.28 TSLP IL4 IL31 IL13 CCL17
2 cytokine receptor binding GO:0005126 9.26 IL4 IL31 IL13

Sources for Neurodermatitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....